Kala Pharms Inc patents expiration
1. Eysuvis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11219596 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10857096 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10945948 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10940108 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9532955 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9737491 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9056057 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9827191 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10058511 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10993908 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10688045 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9393213 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10646436 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Oct 26, 2023 |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 26 October, 2020
Treatment: A method for treating dry eye in a patient; A method for delivering a composition to a mucus membrane; A method for delivering a pharmaceutical agent across a mucosal barrier; Administration to the ey...
Dosage: SUSPENSION/DROPS;OPHTHALMIC
EYSUVIS family patents
2. Inveltys patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9056057 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9532955 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10058511 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US11219597 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10864219 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9737491 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9827191 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10688045 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10646437 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9393213 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 22 August, 2018
Treatment: A method for delivering a composition to a mucus membrane; A method for delivering a pharmaceutical agent across a mucosal barrier; A method of reducing post-surgical pain following ocular surgery; A ...
Dosage: SUSPENSION/DROPS;OPHTHALMIC
INVELTYS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic